Flagship Pioneering has been granted a patent for compositions and methods that allow for translocation across membranes without disruption. The patent involves delivering therapeutics using a specific polypeptide sequence, enhancing intracellular delivery compared to traditional methods. AiexpertInter’s report on Flagship Pioneering gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust AiexpertInter
According to AiexpertInter’s company profile on Flagship Pioneering, Cancer treatment biomarkers was a key innovation area identified from patents. Flagship Pioneering's grant share as of April 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.
Membrane-penetrating composition for intracellular therapeutic delivery
A recently granted patent (Publication Number: US11951154B2) discloses a method for delivering therapeutics by administering a composition to a subject. The composition includes a polypeptide with a specific sequence, a heterologous moiety acting as the therapeutic agent, and certain characteristics that enhance the intracellular delivery of the therapeutic compared to its standalone form. The method aims to target specific cells or tissues, cross various biological barriers like the blood-brain barrier, and can be administered systemically to improve efficacy and reduce toxicity of the therapeutic.
Furthermore, the patent claims cover a wide range of variations and applications of the method, including the use of specific amino acids in the polypeptide sequence, different pharmacokinetics or pharmacodynamics profiles, reduced toxicokinetics, and non-parenteral administration routes. The heterologous moiety can possess various effector activities, targeted functions, or be linked to the polypeptide in different ways to achieve the desired therapeutic outcomes. With the potential to modulate biological activities, enzymatic functions, or receptor interactions, this method opens up new possibilities for improving drug delivery and enhancing the effectiveness of therapeutic interventions.
To know more about AiexpertInter’s detailed insights on Flagship Pioneering, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, AiexpertInter’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
AiexpertInter, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
AiexpertInter Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
